Is the long anticipated event imminent?

Quote

Anonymous

Guest
Olivier Bohoun is looking to move to Sanofi. We report earnings on guidance and our stock surges. The six month moratorium for Stryker is up next week. Syncera is barely mentioned in the earnings report. Tornier merges with Wright Medical, meaning that both of those companies have given up the hope of being bought by one of the big guys. So, any ideas when the end of these dark, dark days will occur?
 






Anonymous said:
Olivier Bohoun is looking to move to Sanofi. We report earnings on guidance and our stock surges. The six month moratorium for Stryker is up next week. Syncera is barely mentioned in the earnings report. Tornier merges with Wright Medical, meaning that both of those companies have given up the hope of being bought by one of the big guys. So, any ideas when the end of these dark, dark days will occur?
Click to expand...

When you go away. Now shut up and sell something.
 












I think you are off a month on the Stryker thing. I believe it was late May when they were looking. I could be wrong.

If Sanofi had waited another 6 mo. then I think Buhon is a stronger candidate. As of now, he has 6 more months on his S&N contract.

If Styker were to make an offer (and I don't think they will), the outgoing CEO is usually asked to stay until the deal closes... So, if Olivier Buhon wants to be the new CEO of the largest French Pharma company, he should NOT make a deal with Stryker that will tie him up for the next 10-12 months... or better yet, QUIT NOW.

It won't matter though. Remember what those Englishmen said? "Meet the new boss... Same as the old boss......... DON'T GET FOOLED, AGAIN"
 






















































Anonymous said:
Olivier Bohoun is looking to move to Sanofi. We report earnings on guidance and our stock surges. The six month moratorium for Stryker is up next week. Syncera is barely mentioned in the earnings report. Tornier merges with Wright Medical, meaning that both of those companies have given up the hope of being bought by one of the big guys. So, any ideas when the end of these dark, dark days will occur?
Click to expand...

You can only hope that someone will come along and rescue you from the cesspool known as Smith & Nephew Advanced Surgical Devices!
 


















Anonymous said:
With every other company merging/bought out, how will Snn even compete?! No one else available for them to acquire.
Click to expand...

You assume that SNN wants to compete. It's obvious fom all of the bonehead decisions they've made that they're not lily interested in competing. Just hold their place in the market & keep doing stupid shit to protect the margins! Beyond that, who really cares?
 






QUOTE=Anonymous;5258539]I think you are off a month on the Stryker thing. I believe it was late May when they were looking. I could be wrong.

If Sanofi had waited another 6 mo. then I think Buhon is a stronger candidate. As of now, he has 6 more months on his S&N contract.

If Styker were to make an offer (and I don't think they will), the outgoing CEO is usually asked to stay until the deal closes... So, if Olivier Buhon wants to be the new CEO of the largest French Pharma company, he should NOT make a deal with Stryker that will tie him up for the next 10-12 months... or better yet, QUIT NOW.

It won't matter though. Remember what those Englishmen said? "Meet the new boss... Same as the old boss......... DON'T GET FOOLED, AGAIN"[/QUOTE]

Pretty spot on analysis, given that Buhon recently said he is not leaving for Sanofi. I don't see a Stryker deal happening. The price is out of whack with reality and Smith & Nephew (I.e. Board and London exchange) consider SNN stock as a national point of pride. They are proud to be one of the largest healthcare companies in UK - never mind that the majority of revenue, profits, and operations are in US.
Look for deal whispers to die after it's leaked to the media that it isn't going to happen. SNN will drop 5% that day, and remain mostly flat until the next round of takeover whispers start up in 4 years.
 












Bohuon not jumping to Sanofi might support that a Stryker buyout is more probable. His SN stock options would go way up in value with a Stryker buyout. Such high value options could provide an incentive for Bohuon to stay at SN in order to cash-in, rather than jumping straight away to Sanofi.
 






Anonymous said:
Bohuon not jumping to Sanofi might support that a Stryker buyout is more probable. His SN stock options would go way up in value with a Stryker buyout. Such high value options could provide an incentive for Bohuon to stay at SN in order to cash-in, rather than jumping straight away to Sanofi.
Click to expand...

British phrasing. You at corporate in London?
 






Top Bottom
Back
Quote